The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

33 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
31
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.EBI
Pharmaceutical
21
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI
Takeda Pharmaceutical
38
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI
Pfizer
1
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI
University of Minnesota
37
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI
Takeda Pharmaceutical
31
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.EBI
University of Navarra
39
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.EBI
Takeda Pharmaceutical
5
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University of Florida
24
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI
Bristol Myers Squibb
1
Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI
Pfizer
21
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI
Boehringer Ingelheim Pharmaceuticals
54
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI
University of Athens
19
Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.EBI
North Dakota State University
33
1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer.EBI
Monash University Malaysia
42
Discovery of matrix metalloproteinase inhibitors as anti-skin photoaging agents.EBI
Hangzhou Normal University
16
Quinazoline-2-Carboxamides as Selective PET Radiotracers for Matrix Metalloproteinase-13 Imaging in Atherosclerosis.EBI
University of Ottawa
29
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI
Bristol Myers Squibb
4
Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.EBI
Sichuan University-University of Oxford Huaxi Joint Centre For Gastrointestinal Cancer
15
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI
Bristol Myers Squibb
53
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.EBI
Jadavpur University
4
Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.EBI
Bolderbiopath
10
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI
Dupont Pharmaceuticals
11
Synthesis and Structural/Functional Characterization of Selective M14 Metallocarboxypeptidase Inhibitors Based on Phosphinic Pseudopeptide Scaffold: Implications on the Design of Specific Optical Probes.EBI
Universitat Aut£Noma De Barcelona
2
Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown.EBI
Dupont Pharmaceuticals
36
Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.EBI
Universidad De Navarra
2
Zinc-Metalloproteinase Inhibitors: Evaluation of the Complex Role Played by the Zinc-Binding Group on Potency and Selectivity.EBI
Paris-Saclay University
18
Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.EBI
Zhaw Zurich University of Applied Sciences
102
Isoindolinone substituted indoles and derivatives as RAS inhibitorsBDB
Boehringer Ingelheim International
407
1,3-thiazol-2-yl substituted benzamidesBDB
Bayer Aktiengesellschaft
72
Triazolo compoundsBDB
Hoffmann-La Roche